research Cutaneous reactions to recombinant cytokine therapy
Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.
Search
for
Sort by
Research
810-840 / 1000+ results 
research Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata
Leflunomide is more likely to help treat alopecia areata than cause it.
research Co-expression of PADI isoforms during progenitor differentiation enables functional diversity
Different PADI isoforms help cells develop diverse functions.
research Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agents
Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.
research Hepatitis C ‐related mixed type vitiligo in a patient with I vemark syndrome
A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.
research Poster abstract: Novel dissolving microarray patches for intradermal delivery of finasteride
Researchers developed a new skin patch that delivers more finasteride into the skin, potentially improving treatment for hair loss and prostate issues.
research Improved humoral immunity and protection against influenza virus infection with a 3D porous biomaterial vaccine
The new vaccine platform led to a stronger immune response and better protection against the flu than the traditional vaccine.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures
A blood pressure drug, diltiazem, may also help treat influenza.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
research Cytokine profiling of alopecia areata phenotypic subsets
Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research A randomized controlled trial comparing total glucosides of paeony capsule and compound glycyrrhizin tablet for alopecia areata
Both treatments for alopecia areata are equally effective and safe.
research Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
research Autoimmune Hair Loss Induced by Alloantigen in C57BL/6 Mice.
Injecting certain cells into mice caused hair loss, which was preventable with a specific inhibitor.
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Assessment of Interleukin-17A and Interleukin-2 Serum Levels in Patients with Alopecia Areata
Higher levels of IL-17A and IL-2 are linked to alopecia areata.
research Comparison of cyclosporine and betamethasone minipulse therapy in management of Alopecia Areata
Oral cyclosporine works better than betamethasone minipulse therapy for treating Alopecia Areata.
research Efficacy of intralesional betamethasone versus triamcinolone acetonide in the treatment of alopecia areata
Triamcinolone acetonide and betamethasone 1.75 mg/ml are both effective for treating alopecia areata.
research 1320 Orchestrated cytotoxic and skin migratory ability lacking self-tolerance: circulating γδT-cells may promote alopecia areata
The role of γδT-cells in causing alopecia areata remains unclear.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
research A Randomized Placebo-Controlled Multicentre Study to Evaluate the Safety and Efficacy of Finasteride for Male Chronic Pelvic Pain Syndrome (Category IIIA Chronic Nonbacterial Prostatitis)
research Prevention and treatment of alopecia areata with quercetin in the C3H/HeJ mouse model
Quercetin effectively treated and prevented hair loss in mice.
research Allergen‐specific immunotherapy improves alopecia totalis in a severe atopic dermatitis patient
Allergen-specific immunotherapy can significantly improve hair loss and dermatitis symptoms in severe cases.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Comparative study between fractional carbon dioxide laser vs intralesional steroid injection in treatment of alopecia areata
FCO2 laser is a better treatment for alopecia areata than intralesional steroids.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research 701 Signaling networks between stem cell precursors, transit amplifying progenitors, and their niche in developing hair follicles
Blocking Prostaglandin D₂ (PGD₂) could help treat hair loss.
![Influence of FHIT on Benzo[a]pyrene-Induced Tumors and Alopecia in Mice: Chemoprevention by Budesonide and N-Acetylcysteine](/images/research/f8f56777-f891-4879-8c45-c87d6aa82563/small/35499.jpg)
research Influence of FHIT on benzo[ a ]pyrene-induced tumors and alopecia in mice: Chemoprevention by budesonide and N -acetylcysteine
Budesonide and N-acetylcysteine reduced tumors and alopecia in mice, regardless of FHIT gene status.
research 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
TAK-279 effectively reduces psoriasis symptoms and is safe.